Paratek Pharmaceuticals, Inc. | TalkMarkets | Page 1
No data available
No data available

People who follow this stock (38)

Latest Posts

About This Stock More About This Stock
Paratek Pharma - Trending Stock
Article By: Jim Van Meerten
Thursday, June 10, 2021 3:01 PM EDT
Revenue expected to grow 270.10% this year and another 16.20% next year. Earnings estimated to increase 92.00% this year and an additional 61.10% next year.
In this article: PRTK
Read
The Daily Biotech Pulse: Amgen Takes 20.5% Stake In BeiGene, Paratek's Mixed Clinical Readout, CareDx Slips On Guidance
Article By: Benzinga
Friday, November 1, 2019 7:38 AM EDT
Here's a roundup of top developments in the biotech space over the last 24 hours.
In this article: AMGN, BGNE, MNK, PRTK, IDYA, CDNA, BLUE Also: HOTH, AGN, AZN, BMY, GSK, RMD, ACOR, ACRX, ALIM, AMAG, BCRX, CERS, IMGN, NURO, RMTI, CELG, VRTX, ABBV, AGIO, REPH, RETA, PRTO, MGNX, OPGN, MGEN, DOVA, DRNA, DCPH, TRVI, OYST, RAPT, ARDS, MIRM, ITRM, COCP, CYCN, GMAB
Read
Paratek Pharmaceuticals, Inc. (PRTK) Catches Eye: Stock Up 27.3%
Article By: Zacks Investment Research
Thursday, August 24, 2017 10:29 AM EDT
Paratek Pharmaceuticals, Inc. was a big mover last session, as the company saw its shares rise over 27% on the day. The move came on solid volume too with far more shares changing hands than in a normal session.
In this article: PRTK Also: ALXN
Read
Week In Review: Cathay Fortune Pays $186 Million For German Diagnostic Company
Article By: ChinaBio® Today
Saturday, April 29, 2017 1:45 PM EDT
Cathay Fortune International, a Shanghai healthcare private equity firm, will acquire Berlin's Epigenomics AG for $186 million in cash. Cathay will acquire Epigenomics through a subsidiary, Blitz F16-83.
In this article: BMY, LLY, MRK, PFE, EPGNF, AMRI, PRTK
Read
Paratek Pharmaceuticals Scores Clean Sweep In Pivotal Test Of New Drug For Treating CABP - Stock Jumps Dramatically
Article By: Lorimer Wilson
Tuesday, April 4, 2017 11:34 AM EDT
Paratek Pharmaceuticals, Inc. shares shot up 36% in pre-market trading on Tuesday as investors reacted to the Boston biotech’s proclamation of a clean sweep for its pivotal test of its new antibiotic omadacycline.
In this article: PRTK
Read

Latest Tweets for $PRTK

No tweets yet!

PARTNER HEADLINES